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Amyloid beta (Aβ) peptides are known to accumulate in the brain of patients with Alzheimer’s disease (AD). However, the link
between brain amyloidosis and clinical symptoms has not been elucidated and could be mediated by secondary neuropathological
alterations such as ﬁber tracts anomalies. In the present study, we have investigated the impact of Aβ overproduction in APPxPS1
transgenic mice on the integrity of forebrain axonal bundles (corpus callosum and anterior commissure). We found evidence of
ﬁber tract volume reductions in APPxPS1 mice that were associated with an accelerated age-related loss of axonal neuroﬁlaments
and a myelin breakdown. The severity of these defects was neither correlated with the density of amyloid plaques nor associated
with cell neurodegeneration. Our data suggest that commissural ﬁber tract alterations are present in Aβ-overproducing transgenic
miceandthatintracellularAβ accumulationprecedingextracellulardepositsmayactasatriggerofsuchmorphologicalanomalies.
1.Introduction
Alzheimer’s disease (AD)is ahighly prevalentneurodegener-
ative disease accompanied by gradual and irreversible behav-
ioral and cognitive impairments. Brain lesions observed
during the course of AD involve two main aspects: extr-
acellular amyloid-beta (Aβ) deposition in the senile plaques
and intracellular tau accumulation forming neuroﬁbrillary
tangles and promoting cytoskeletal disorganization. Current
research on AD is largely guided by a dominant pathogenic
theory, the so-called amyloid cascade hypothesis [1]. Reg-
ularly commented on and amended [2], this model posits
accumulation of Aβ in the brain as a key primary event that
determines the onset of other brain alterations (e.g., synaptic
and neuronal death), ﬁnally leading to the dementia. Early
onset familial forms of AD are indeed associated with muta-
tions in diﬀerent genes (amyloid precursor protein (APP)
and presenilins 1&2, (PS1&2)) involved in the biosynthesis
of Aβ. Dysfunction of these genes is logically thought to alter
the rate of APP cleavage, resulting in exaggerated Aβ pro-
duction. High levels of brain Aβ and associated parenchymal
amyloid plaques are key phenotypes described in transgenic
mice overexpressing one or more of these mutated genes
(see [3] for review). These mice subsequently develop
neuropathological alterations and behavioral impairments
mimicking AD phenotype [4, 5].
The exact impact of brain Aβ accumulation on clinical
symptoms remains to date diﬃcult to decipher, both in
AD patients and in animal models of the disease. Clinico-
pathological correlative analyses have led to mitigated con-
clusions [6–10], and it is now considered that preplaques
Aβ assemblies are the most deleterious species [11] while
aggregated insoluble deposits have a reduced pathogenicity
[12].
In addition white matter anomalies are described in
AD patients, presumably in association with cerebrovascular
impairments [13], and in transgenic mice modeling brain
amyloidosis [14]. These lesions can be detected through
conventional postmortem neuropathological examination,
but also in vivo by means of dedicated techniques such
as diﬀusion tensor imaging [15, 16], and it has even been
proposed that white matter defects are potent diagnostic2 Journal of Aging Research
biomarkers for AD [17, 18]. The integrity of axonal bundles
constituting white matter ﬁber tracts is particularly compro-
misedduringthecourseofAD,evenattheveryearlystagesof
the disease [19, 20]. Alterations of ﬁber tracts have obvious
functional consequences: disconnection of neural networks
occurs following ﬁbers loss, leading to diaschisis and cortical
disorganized activity [21, 22]. Also, disruption of myelin in
axonal bundles might have deleterious eﬀects on neuronal
communication by altering propagation of action potentials
and increasing brain energy expenditure (see [23, 24]f o r
reviews).
White matter alterations in ﬁber tracts are related to de-
myelination and also to other axonal morphological defects
that can ultimately lead to degeneration and loss of ﬁbers.
It has been demonstrated that AD patients show concurrent
decreased axonal densities [25] and myelin breakdown [23].
Interestingly,experimentalstudiesinADanimalmodelshave
shownthataxonalpathologycanbedri-venbyAβdeposition
in the brain [26–28].
The aim of the present study was to further evaluate ﬁber
tracts changes in a double APPxPS1 mouse transgenic model
with aggressive Aβ-related pathology [29–31]. Two commis-
sural ﬁbers tracts (corpus callosum and anterior commis-
sure)thatshow signiﬁcant alterationsin ADpatients [32,33]
were selected and analyzed: axonal integrity was quantiﬁed
by assessing antineuroﬁlament immunostainings. Myelin
densitywasevaluatedbyhistochemistryusingagoldchloride
staining that provides high contrast and spatial resolution
[34, 35] and that has previously been used to underline
myelin alterations in AD transgenics [36]. Age-dependent
changes were detected in both ﬁber tracts of APPxPS1 mice.
Wetentativelycorrelatedtherelationshipbetweenthesemor-
phological anomalies and Aβ deposition.
2.MaterialsandMethods
2.1. Transgenic Mice. Female transgenic APP/PS1 mice
(Thy1 APP751 SL (Swedish mutation KM670/671NL, Lon-
don mutation V717I introduced in human sequence
APP751) × HMG PS1 M146L) modeling early onset and
progressive cerebral amyloid deposition were used [29, 30,
37–39].HeterozygousAPP/PS1micewereobtainedbycross-
ing APP(+/wt)/PS1(wt/wt) with APP(wt/wt)/PS1(+/+) mice
established on a C57bl6/CBA background. Note that, due to
the use of homozygous PS1(+/+) mice, no wild-type mice
could be generated from the breeding scheme. PS1 litter-
mates were therefore used as control animals. PS1 mice have
been described in previous studies to be devoid of neuro-
pathological alterations [30, 37] and hence constitute good
controls(age-matchedlittermateswithnoovertphenotypes)
for analyzing APPxPS1 transgenics. A total of 28 mice
were evaluated. Two age groups were analysed: “young” (2
months: 8 APP/PS1 and 7 PS1 mice) and “old” animals (24
months: 6 APP/PS1 and 7 PS1 mice).
2.2. Histology
2.2.1. Brain Processing. Following decapitation, the brains
were extracted, ﬁxed in 10% buﬀered formalin, and stored
overnight in a solution of 20% glycerin and 2% dimethylsul-
foxide in 0.1M phosphate buﬀer for cryoprotection. Brains
were subsequently sectioned into 40µm thick coronal sec-
tionsonafreezingmicrotome.Twelveseriesofsectionsrang-
ing from the frontal to the occipital poles were collected and
stored at −20◦C in cryoprotectant before use.
2.2.2. Myelin Staining. Myelin staining was performed on a
batch of serial sections using a protocol derived from [34]
with some modiﬁcations. Brain sections were rinsed with
0.1M phosphate buﬀer (PB) mounted on Superfrost+ slides
and dried overnight at 50◦C. The slides were then rinsed
in 0.02M phosphate saline buﬀer (PBS). Two milliliters of
freshly prepared 0.2% gold chloride (Carlroth, Karlsruhe,
Germany) dissolved in 0.02M PBS was added on each glass
slidestocompletelycoverthesection.Incubationwascarried
o u ta tr o o mt e m p e r a t u r e( R T )f o r2h o u r si no b s c u r eh u m i d
chambers. The tissue was brieﬂy rinsed in water, ﬁxed in
2.5% sodium thiosulfate for 5 minutes, and ﬁnally rinsed in
runningtapwaterfor30minutes.Sectionswerecoverslipped
with Eukitt after dehydration in graded alcohols and clearing
in xylene.
2.2.3. Axonal Immunostaining. Free-ﬂoating sections were
rinsed in PB and pretreated with 0.3% H2O2 in methanol for
10minutestoblockendogenousperoxidaseactivity.Nonspe-
ciﬁc antigenic sites were blocked by 5% goat serum in PBS-
Triton X-100 (1 hour at RT). Sections were then incubated
overnight at RT with a C-terminal antineuroﬁlament M
(145KD) primary antibody (AB1987; Chemicon, Temecula,
Calif) diluted 1:1000 in serum. The following day sections
were incubated in a secondary biotinylated antirabbit anti-
body solution (Sigma, St. Louis, Mo; 1:200, 1.5 hours at
RT) and then in an avidin-biotin peroxidase complex (ABC)
reagent (Vectastain Elite ABC-Kit, Vector Laboratories, USA,
1:800, 1.5 hours at RT). The sections were rinsed 3 × 10
min between all incubation steps. The immunoreaction was
visualized with 3,3
 -diaminobenzidine (DAB) under micro-
scopical control. The reaction was stopped when the signal-
to-noise ratio was considered optimal. The sections were
ﬁnally mounted on superfrost slides, dried, and processed in
alcohols/xylene before being coverslipped.
2.2.4. Amyloid Plaques and Intracellular Aβ. One series of
section was stained by Congo red according to the standard
technique (30 minutes in a 80% ethanol solution saturated
with Congo red and sodium chloride) [30, 40]. Another
series of sections was immunostained with the primary 4G8
monoclonal anti-Aβ antibody (Signet Laboratories, Ded-
ham, Mass; 1:10000, incubation overnight at RT). A high
dilution of the biotinylated 4G8 antibody was used to avoid
cross-reaction with APP and to solely immunodetect Aβ
[41]. Thanks to biotin complexion, no secondary antibodies
were used and tissue was directly incubated in the ABC Kit
solution before being developed in DAB.
2.2.5. Evaluation of Neurodegeneration. Staining of degener-
ating neurons was performed using the Fluoro-Jade B dyeJournal of Aging Research 3
[42] with a slightly modiﬁed protocol [43]. Glass-mounted
sections were passed through absolute ethanol and 75%
ethanolfollowedbya1-minuterinseindistilledwater.Tissue
was then incubated in 0.06% potassium permanganate solu-
tion for 15 minutes with slight agitation and rinsed before
staining in Fluoro-Jade B (Histo-Chem., Jeﬀerson, Ark;
0.001% solution prepared in 0.1% acetic acid; 30 minutes at
RT). After extensive rinsing in distilled water, sections were
dehydrated, cleared in xylene, and coverslipped.
2.3. Quantitative Image Analysis and Statistics
2.3.1.MyelinDensities. AllslidesweredigitizedusingaSuper
CoolScan 8000 ED scanner (Nikon, Champigny sur Marne,
France) with a 4000dpi in-plane digitization resolution
(pixelsize6.35μm2).Quantiﬁcationofgoldchloridestaining
was performed, in two regions of interest (corpus callosum
and anterior commissure), by relative optical density (ROD)
analysis, a method that has already been used to evaluate
myelin stainings [44]. In the rostral brain, 3 sections were
selectedtoanalyzemyelinattheleveloftheanteriorcommis-
sure(bilateralcountings,i.e.,n = 6samples/mouse).Forthe
analysisof myelination of the corpus callosum,7 sections per
animal were selected, spanning the rostrocaudal extent of the
region; the ROD analysis was performed on the total corpus
callosum volume and also separately in its anterior and post-
erior parts (see below).
Measure of mean grey value was semiautomatically per-
formed in the two regions of interest using Photoshop CS2
software (Adobe, Paris, France). ROD was obtained after
transformation of mean grey values using the formula ROD
= log10 (256/(mean grey value)). Values of background stain-
ing were taken in adjacent tissues with no myelin staining
(upper cortical layers or striatum) and subtracted to get a
ﬁnal densitometric evaluation of myelin stain.
While 2-month-old APPxPS1 mice were devoid of amy-
loid plaques, Aβ deposition was very extensive in aged APP/
PS1 transgenics. Notably many plaques were observed in the
corpus callosum and in the anterior commissure. Obviously
the gold chloride negatively stained areas corresponding to
plaque occupancy might artiﬁcially decrease the local mean
grey values. To correct for this bias in old mice, plaques
surfacesweremanuallyremovedfromanalyzedregionsofin-
terest before processing ROD calculations.
2.3.2. Fiber Tracts Atrophies. The sizes (surface area from
coronal sections) of both the corpus callosum and the an-
terior commissure were evaluated by manually outlining the
structures on digitized scans of myelin-stained brain sec-
tions (see Figure 1). Three measures of ﬁbers tracts size were
taken: (1) in the anterior corpus callosum (sampling bet-
ween 4.9 and 3.22mm/interaural reference in the Paxinos
and Franklin atlas [45], n = 4 sections/mice), (2) in the
posterior corpus callosum (3 sections taken between 1.5 and
2.58mm/interaural reference), and (3) in the anterior com-
missure (sampling between 4.18mm and 4.9mm/interaural
reference, n = 3 sections analyzed bilaterally/mice). For each
region of interest, area size measurement was calculated by









Figure 1: Myelin stain of the corpus callosum. On frontal sections,
staining of the myelin using the gold chloride method allows to de-
lineate the perimeter of the corpus callosum (CC) at the rostral (a)
and caudal (b) levels. On the basis of axon orientation and staining
intensities, adjacent ﬁber tracts (CB: cingulate bundle; dHC: dorsal
hippocampalcommissure;EC:externalcapsule)areclearlyoutlined
allowing accurate visualization of the corpus callosum borders.
Scale bars: 200μm.
2.3.3. Axonal Neuroﬁlament Densities. Neuroﬁlament im-
munostained sections were digitized as described above for
myelin-stained sections. Assessment of neuroﬁlament im-
munoreactivity was performed in the same two regions of
interest (corpus callosum, n = 7 sections/mouse; anterior
commissure,n = 3sections/mouse)bymeansofRODanaly-
sis.
2.3.4. Extracellular Amyloid Loads in Old Mice. Evaluation of
the extracellular amyloid load was only performed in the 24-
month-old APP/PS1 mice as almost no Congo red positive
deposits were observed in young double transgenic mice.
Plaques loads were quantiﬁed using computer-based
thresholding methods [46]. Scans were prepared using
Photoshop CS2 to outlineselectedregions ofinterest. Images
were then processed with ImageJ freeware (Rasband, W.S.,
ImageJ, US National Institutes of Health, Bethesda, Md,
USA, http://rsb.info.nih.gov/ij/, 1997–2006) using a dedicat-
ed macrocommand that extracts amyloid deposits from4 Journal of Aging Research
background tissue with no user inputs. Regional amyloid
loads were expressed as percent of tissue surface stained by
the Congo red dye that corresponds to the proportion of
plaques volume. Amyloid loads were evaluated (1) in the
whole brain [30], (2) in the rostral isocortex that is richly
innervated by axons passing through the anterior corpus
callosum, and (3) directly in the two ﬁber tracts that were
investigated in the present study (anterior commissure, cor-
pus callosum).
2.3.5. Intracellular Amyloid Loads in Young Mice. Intra-
neuronal Aβ immunoreactivity was not found in aged
mice (as already reported for this mouse line [38]) and
was quantiﬁed only in the young APPxPS1 mice. Two
sections/animals were selected at the level of the frontal
cortex, and a semiquantitative analysis, based on a four-
point scale, was performed on both hemispheres to evaluate
levels of neuronal immunostainings in the cortex: 0: no
obvious positive staining; (1): weak intracellular staining;
(2): moderate staining; (3): strong staining. For each animal
semi-quantitative analyses were hence performed in four
ﬁelds (2 slices; bilateral countings).
To evaluate the connection properties of Aβ-containing
neurons and their possible participation to commissural
tractsweperformedanaxonaltracingstudyintwowild-type
mice (3 month-old): biotinylated dextran amine (BDA), an
anterograde tracer, was stereotactically injected in the corti-
calregionswhereAβ-positive neuronswereconcurrentlyob-
served in APPxPS1 transgenics, allowing ﬁne visualization of
cell bodies and of neurites. Surgery and immunolabeling of
BDA stained axons were performed using standard protocols
as previously described [47, 48].
2.3.6. Statistics. Student’s t-tests were performed using Sta-
tistica 7 (StatSoft, Inc., Tulsa, USA). Results were considered
statistically signiﬁcant at P<0.05.
3. Results
3.1. Altered Volumes of Fiber Tracts in APPxPS1 Mice. Gold
chloride myelin staining, as compared to standard stains
(e.g.,HE or Nissl stains), allowed to precisely outline the area
of the corpus callosum. In particular, delineating the corpus
callosum from adjacent white matter tracts (e.g., cingulate
bundle, dorsal fornix, and dorsal hippocampal commissure)
was greatly facilitated by the myelin staining (Figure 1).
Lateral limits of the corpus callosum and borders of the
external capsule were identiﬁed by a horizontal-to-vertical
shift in ﬁber orientation. Also, the anterior commissure was
easily identiﬁed and outlined in the gold chloride-stained
sections (see Figure 5(b)).
3.1.1. Young Mice. The size of the anterior commissure
was similar in 2-month-old PS1 mice and in age-matched
APPxPS1 transgenics (t(13) = −0.58; Figures 2(b) and 5(b)).
On the contrary, the corpus callosum size was signiﬁcantly
decreased in young APPxPS1 as compared to controls
(t(13) = 3.501, P<. 005; Figures 2(a) and 5(a)). Subregional
analysis indicated a signiﬁcant reduction in the size of the
rostral corpus callosum of young APPxPS1 mice (t(13) =
3.743, P<. 005) while there was no diﬀerence between geno-
types in the size of the posterior corpus callosum (t(13) =
0.136, ns).
3.1.2. Old Mice. With aging, a signiﬁcant increase in the size
of axonal bundles was observed in PS1 control mice (corpus
callosum: t(12) = 3.858, P<. 005; anterior commissure:
t(12) = 4.275, P<. 005). From pilot studies, we have ob-
served the same developmental traits in wild-type C57bl6
mice (increased volumes of the corpus callosum and of the
anterior commissure with aging; data not shown) precluding
the possibility that the PS1 transgene by itself triggered ab-
normal(increased)ﬁbertractgrowthinPS1transgenicmice.
On the other side, age-dependent enlargement of com-
missural bundles was clearly not evidenced in the double
APPxPS1 transgenics: in this genotype, the size of the corpus
callosumremainedconstantbetween2and24months(t(12)
= 1.850, ns) and the surface area of the anterior commissure
even undergoes slight atrophy with aging (t(12) = 2.284,
P<. 05). Hence, strong diﬀerences between genotypes were
observed in 24-month-old mice with APPxPS1 transgenics
showing, in comparison to PS1 controls, decreased white
matter surface areas. This was observed at the level of the
anterior commissure (t(11) = 6.388, P<. 0001) and of
the corpus callosum (total corpus callosum: t(11) = 4.653,
P<. 001; anterior part: t(11) = 5.404, P<. 0005). The only
posterior region of the corpus callosum did not show sig-
niﬁcant atrophy in old APPxPS1 mice (t(11) =1.492, ns).
3.2. Potentiation of Axonal Neuroﬁlament Loss in Old
APPxPS1 Mice. Densities of axonal neuroﬁlaments in the
corpuscallosumandintheanteriorcommissurewerequant-
iﬁed using ROD analysis of immunostainings. In 2-month-
old mice axonal densities were similar in both genotypes
whatevertheﬁbertractconsidered(allP’s >. 35).Withaging,
a severe decrease in neuroﬁlament density was observed,
both in APPxPS1 and PS1 mice, in the corpus callosum
(Figures 2(c) and 3(a)) and in the anterior com-missure
(Figures 2(d) and 3(b))( a l lP’s <. 0001). Age-related
reduction of neuroﬁlament density was, however, largely
more prominent in old APPxPS1 mice than in age-matched
PS1 controls. This accelerated loss of axonal neuroﬁlaments
in old APPxPS1 mice was further conﬁrmed by statistical
analysis in the diﬀerent subregions of the corpus callosum
(APPxPS1 < PS1: all P’s <. 0001) and 2) and also at the level
of the anterior commissure (t(10) = 4.16; P<. 005).
3.3. Abnormal Myelination in Old APPxPS1 Mice. ROD
analysis of gold chloride stainings in 2-month-old mice indi-
cated comparable myelin densities in PS1 and APPxPS1
transgenics (corpus callosum: t(13) = 0.318, ns, Figures 2(e)
and5(a);anteriorcommissure:t(13) =1.277,ns,Figures2(f)
and 5(b)).
The myelin density of the anterior commissure was not
aﬀected by aging (PS1: t(12) = 1.292, ns; APPxPS1: t(12) =


























































































































































Figure 2: Summary of quantitative morphological analysis. The analysis was focused on the corpus callosum (left column) and on the
anteriorcommissure(rightcolumn).MorphologicaldatawerecollectedinoldandinyoungmicefromPS1andAPPxPS1genotypes.(a)-(b).
Size of ﬁber tracts (pixels). (c)-(d). Relative optical densities (ROD) of neuroﬁlament M145Kd (axons) immunostainings. (e)-(f). Relative
optical densities of gold chloride (myelin) stainings. See text for details. All measures are illustrated by means + SEM in each experimental
groups. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001.
in 24-month-old PS1 and in age-matched APPxPS1 mice
(t(11) = 0.679, ns).
On the other hand, an increase of the myelination of the
corpus callosum was observed when comparing 2-month-
and 24-month-old PS1 mice (t(12) = 2.823, P<. 05). Noti-
ceably, this increase in myelin density was signiﬁcant in the
rostral corpus callosum (t(12) = 4.171, P<. 005) but not in
its posterior part (t(12) = 0.461, ns). Contrarily to PS1 mice,
such an age-related increase of callosal myelination was not
observed in APPxPS1 mice (t(12) = 0.7, ns). Consequently
decreased myelin staining was evidenced in 24-month-old
APPxPS1 mice when compared to old PS1 controls (total
corpus callosum: t(11) =3.332, P<. 01). Diﬀerences between







Figure 3: Representative illustration of neuroﬁlament immunos-
tainings. Immunodetection of axonal neuroﬁlaments is illustrated
at the level of the corpus callosum (a) and anterior commissure
(b) in both young and old PS1 and APPxPS1 transgenics. See text
for details concerning age and genotype eﬀects. Black arrow heads
point to positive axonal enlarged varicosities in old APPxPS1 mice.
Scale bars: 100μm.
corpus callosum (t(11) = 3.512, P<. 005), while no dif-
ference between PS1 and APPxPS1 mice were evidenced in
more caudal regions (t(11) = 1.9; ns).
Qualitative examination of myelin-stained sections was
then performed in old APPxPS1 mice. No evidence of mye-
lin breakdown (debris) was found in the large myelinated
bundles of the corpus callosum. However, in comparison
to control animals, myelin appeared to be fragmented in
the isocortex and hippocampus of APPxPS1 mice (Figure 4).
Myelin material was often detected under the form of
small tortuous segments with bead-like varicosities. These
morphological anomalies, absent in young APPxPS1 mice,
were found at the vicinity of Aβ deposits but also in the











Figure 4: Myelin stains in the cingulate cortex. In young PS1
and APPxPS1 mice myelinated axons in the cingulate cortex have
a radial organization that is preserved in old PS1 mice but is
severely disorganized in old APPxPS1 transgenics (lower right
photo: optically empty areas correspond to amyloid plaques and are
identiﬁed by black asterisks). Scale bar: 100μm.
3.4. Relationship with Aβ Pathology and with Neurodegenera-
tion. Congo red positive aggregates were detected and
quantiﬁed in the anterior commissure (mean load= 2.8%;
min = 1.6%; max = 6%) and in the corpus callosum
(mean load = 2.2%; min = 1.6%; max = 2.7%) of old
APPxPS1 mice (Figures 6(a) and 6(b)). Correlative anal-
ysis did not reveal signiﬁcant associations between local
amyloid loads in ﬁber tracts and decreased neuroﬁlament
immunoreactivity/myelin densities (all P’s >. 111). Also
there were no correlations between the sizes of the corpus
callosum/anterior commissure and total or cortical amyloid
loads (all P’s >. 196).
In addition to amyloid plaques loads, intraneuronal Aβ
was semiquantitatively assessed in the isocortex of young
APPxPS1 mice. As expected from previous observations,
positive labeling was detected using the 4G8 antibody in a
subset of cells. Staining was mainly observed in deep cortical
layers(V)involvingadistinctivebandoflargepyramidalcells
(Figures 6(c) and 6(d)). There were no direct correlations
between levels of intracellular Aβ that may signiﬁcantly vary
from one animal to the other (mean = 7.8; min = 4.5;
max = 11.5) and neuroﬁlament and myelin densities (all P’s
>. 119). Interestingly, tracing experiments underlined that
the deep layers of the cortex, where speciﬁcally Aβ-positive
neurons were observed in the double transgenics, are the
source of dense callosal projections (Figure 6(e)). Therefore,
althoughnotightcorrelationswerestressedbetweentheden-
sity of intracellular Aβ and the magnitude of axonal ano-
malies, we evidenced that callosal ﬁbers still originate from
a subpopulation of neurons overproducing toxic Aβ species.
The Fluoro-Jade B dye was used to assess neurodegener-
ation in APPxPS1 mice. No positive neurons were detected
in the studied animals (data not showed). In particular no







Figure 5: Representative illustration of myelin stains of ﬁber tracts. Myelin (gold chloride) stains are illustrated at the level of the corpus
callosum (a) and anterior commissure (b) in both young and old PS1 and APPxPS1 transgenics. See text for details concerning age and
genotype eﬀects. Black arrow heads ((a) lower right photo) point to circular unstained areas corresponding to amyloid plaques in the corpus
callosum of old APPxPS1 mice. Scale bars: 100μm.
with high densities of Aβ-positive neurons (see above). Only
the core of amyloid deposits and the surrounding degenerat-
ing dystrophic neurites as well as reactive astrocytes were de-
tected with Fluoro-Jade B in old APPxPS1 mice (see [49, 50]
for similar observations).
4. Discussion
Neuroimaging assessment repeatedly underlined white mat-
ter changes in AD patients. Evidence from diﬀusion tensor
imaging of ﬁber tracts suggests for instance that during the
course of the disease there is a loss of barriers that restrict
water motion and tissue anisotropy of white matter. These
observations have obviously a neuropathological counter-
part: anomalies of diﬀusion could reﬂect either loss of axons,
demyelination, and/or oligodendroglial pathology. To date
only a few studies have investigated the source of white
matter/ﬁber tracts impairments in AD patients and in aged
nondemented subjects [51, 52]. Recent attempts to deci-
pher the origin and mechanisms of such morphological
alterations have been performed in animal models of the
disease [36, 53, 54] but a systematic screening of ﬁber tracts
anomalies related to AD pathology is still lacking in these
models.
The goal of our work was therefore twofold: (1) to assess
in an AD mouse model the severity of ﬁber tracts alteration
across aging and (2) to reﬁne the understanding of their his-
tological substratum and in particular to evaluate the rela-
tion between Aβ peptide deposition and the occurrence of
the white matter anomalies.
4.1. Fiber Tract Atrophies in APPxPs1 Mice. Our quantitative
analysis underlines the decreased size of forebrain ﬁber bun-
dles in old APPxPS1 mice displaying concurrent severe brain
amyloidosis. Volume reductions were observed in the corpus
callosum, as already reported in AD transgenics [14, 30, 55]
but also, as a novel ﬁnding, at the level of the anterior com-
missure.Theseanomaliesdonotpurelymimicanage-related
atrophy and might also reﬂect a lack of normal development
ofﬁbertractsinAPPxPS1mice(seealso[30]forsimilarcon-
clusions).
As mentioned above, atrophy of the corpus callosum
has previously been reported in AD transgenic mouse
models but more interestingly is also classically depicted
in AD patients (e.g., [33]). We found that atrophy of the
corpus callosum, in our APPxPS1 transgenics, largely pre-
dominates in its anterior part. Although not constantly
reported, similar ﬁndings concerning regional atrophies of
the corpus callosum have been described in human patients
[21, 56]. In addition to callosal atrophy we also evi-
denced, in old APPxPS1 mice, a reduction in size of the
anterior commissure that might ﬁnd a parallel with recent
observations in AD patients [32].
Supporting size reduction of ﬁber tracts we evidenced
a very strong decrease of axonal neuroﬁlament densities
in the double transgenics, outclassing the “normal” loss of
neuroﬁlament we observed in aged control PS1 mice (and
in wild-type mice; data not shown). We also substantiated
a signiﬁcant myelin breakdown in APPxPS1 mice. The loss
of myelin in aged APPxPS1 mice appears however to be
limitedincomparisontothehighandaccelerateddecreaseof
neuroﬁlament densities these mice undergo. As evidenced by
correlative analysis, there were no strict linear relationships
between ﬁber tracts atrophies and neuroﬁlament or myelin
markers. For instance, we found a reduced size of the
corpuscallosuminyoungAPPxPS1micewhiletheseanimals
showed the same neuroﬁlament and myelin densities as
control PS1 mice—such observations emphasizing similar










Figure 6: Aβ pathology in APPxPS1 mice. 24-month-old APPxPS1 mice display heavy cortical amyloid burden as evidenced by Congo
red staining (a). Congophilic plaques were also observed in white matter tracts such as the corpus callosum (outlined rectangular area in
magniﬁcation in (b)) and the anterior commissure (outlined in a and pointed by a black arrow head). In young APPxPS1 mice dense core
amyloid plaques were virtually absent but strong Aβ intraneuronal accumulation, as revealed by 4G8 immunostainings, was detected in
infragranular cell layers ((c), magniﬁed view in (d)). (e) Biotinylated dextran amine, an anterograde tracer, was injected in the deep layers
of the isocortex (left hemisphere) at the locus where Aβ-containing neurons were found in APPxPS1 transgenics. These neurons send their
axons through the corpus callosum and cingulum bundle, cross the midline, and innervate the opposite (right) hemisphere. Scale bars:
1000μm (a), 100μm ((b), (c), and (d)), and 500μm( e ) .
tissue might indeed testify for an early net loss of callosal
ﬁbers in young APPxPS1 mice. Also we found that ﬁber
tracts continue to grow and pursue their myelinisation in
normal mice between 2 and 24 months of age while neuro-
ﬁlament densities in the same mice concurrently display a
50% drop—this observation can be explained (1) by a pro-
gressive enlargement of myelin sheets with aging that will
maximize space around individual axons and consequently
decrease their density and (2) by a concurrent diminution of
the expression of axonal neuroﬁlament proteins that has pre-
viously been described in aged animals [57].
4.2. Substratum of Fiber Tract Anomalies: Altered Myelinisa-
tion. We have investigated various sources of neuropatho-
logical alterations that could explain ﬁber tracts atrophies
in our APPxPS1 model. It has been claimed that a demyeli-
nation process is observed during the course of AD and is
a trigger in the physiopathogeny of this disease [23, 24].
It has even been proposed that myelin breakdown in AD
initiates a vicious circle as release of iron after demyelination
might promote Aβ production and toxicity which in turn
aﬀects myelin integrity [58]. In the present study we indeed
observed qualitative anomalies of axonal myelination in oldJournal of Aging Research 9
APPxPS1 mice accumulating Aβ. Similar observations, that
might deserve conﬁrmation and further characterization
at the ultrastructural level using electron microscopy, have
been recently reported in AD Tg2576 and APPxPS1 mice
but only in the neuropil in close association with amyloid
plaques [54]. In our study myelin alterations, including
fragmentation and spheroid-like pathological enlargements,
were observed in axons passing through the gray matter,
even at distance of amyloid deposits, but not easily in
dense ﬁber tracts under light microscopy. At the quantitative
level, the overall myelination of the corpus callosum was
found to be signiﬁcantly decreased in old APPxPS1 mice.
However no diﬀerences were observed between genotypes
at the level of the anterior commissure, suggesting that loss
of myelin is heterogeneous and does not aﬀect similarly
all axonal bundles. Actually, myelination kinetics during
ontogenesis might considerably vary from one brain region
to the other [44, 59]. It is hence possible that brain areas
and ﬁber tracts with late or early myelination are diﬀer-
entially impeded during (pathological) aging [60, 61]. In
addition, it is known that the corpus callosum, in terms of
phylogeny, is a neural pathway that is only found in placental
mammals while the anterior commissure is a more ances-
tral axonal tract [62], adding supplementary diﬀerences bet-
ween the two ﬁber bundles that could explain regional
discrepancies in age-dependent (de)myelination processes.
Interestingly, it has been shown that oligodendrocytes have a
reduced myelin turnover in regions lately myelinated during
ontogenesis[63].Thiswouldimplyadiminishedcapacityfor
myelin repair in these regions, especially under challenging
conditions (oxidative stress, excitotoxicity, inﬂammation,
etc.) because oligodendrocytes are a strikingly vulnerable
population of cells [23]. Toxicity of Aβ on oligodendrocytes
has been evidenced in several reports [36, 64]w i t he ﬀects
ranging from mitochondrial dysfunction to apoptosis and
cell death. The involvement of oligodendrocytes in the mye-
lin anomalies depicted in our APPxPS1 transgenics would
deserve further analysis. In particular, it would be interesting
to document possible anomalies at the level of myelin basic
proteins.
4.3. Substratum of Fiber Tract Anomalies: Axonal Pathology.
Decreased sizes of the corpus callosum and of the anterior
commissure in APPxPS1 mice might be related to defects
in ﬁber myelination but, according to our observations, can
alsobelinkedtoanacceleratedlossofaxonalneuroﬁlaments,
possibly reﬂecting loss of ﬁbers.
We have previously reported vascular alterations (vessel
voids and reduction of vessel lengths) by means of in vivo
magnetic resonance angiography in the APPxPS1 transgenic
mouse model used in the present study [65]. These lesions,
closely associated with amyloid angiopathy, could contribute
to the described axonopathies [66].
Anomalies in regulatory proteins involved in axonal
structural plasticity during AD could also be causative [67]
but remain to be ﬁrmly established in our transgenic mouse
model.
AxonopathyhaspreviouslybeenreportedintheAPPxPS1
mouse line but was originally evidenced at the spinal
level [31]. Our results highlight that axonal pathology in
APPxPS1 mice also concerns forebrain ﬁber tracts. Inter-
estingly, it has been demonstrated that AD patients sustain
axon loss [25, 68] but the magnitude of the eﬀects we
reported (large drop in neuroﬁlament densities, ﬁrst in
aged PS1 control mice and second, greatly accentuated, in
aged double APPxPS1 transgenics) has not been reported
up to now to the best of our knowledge. Bussi` eres and
collaborators [69] have demonstrated that neurons from AD
brains expressing neuroﬁlament proteins with medium- and
heavy- molecular-weight subunits (SMI-32 immunoreactive
neurons)constituteanexquisitevulnerablesubpopulationof
cells during disease process. These neurons have a speciﬁc
laminar distribution in the cortex compatible with their
participation to corticocortical connections relying on ﬁber
tracts and axonal fasciculi. Back to our experimental data, it
would be appealing to speculate that loss of axonal neuro-
ﬁlaments in the anterior commissure and corpus callosum
indeed implies pathological events at the level of eﬀerent
neurons in speciﬁc brain regions (e.g., isocortex area for
callosal neurons). We did not ﬁnd however any evidence of
cell degeneration in old APPxPS1 mice (see also [50]f o r
similar report). On the other side we cannot totally preclude
that APPxPS1 mice have decreased neuronal densities in
projections regions resulting from earlier insults, with no
overt signs of active degeneration in the oldest animals. A
substantial (30%) loss of neurons has been described in the
hippocampus of old APPxPS1 mice [37, 70]. It is not yet
known if a similar loss occurs in isocortical areas and further
analysis will be required to ascertain this point.
4.4. Substratum of Fiber Tract Anomalies: Role of Aβ-Positive
Lesions. In accordance with previous studies (e.g., [37,
71]), we did not ﬁnd evidence of a clear pathogenicity
of aggregated (Congo red positive) insoluble Aβ deposits.
The density of amyloid plaques did not predict, in old
APPxPS1 mice, the magnitude of ﬁber tracts anomalies
these mice sustained. In a previous study we evidenced that
axon terminals of cortico-cortical ﬁbers endorse degenera-
tion when contacting amyloid plaques [26] but this local
synaptotoxicity was not associated with clear retrograde
degeneration. In another study of Jantaratnotai [27]a x o n a l
damage and demyelination were reported following in vivo
Aβ injections in the corpus callosum. However these eﬀects,
obtained in a context of sudden and potentiated toxicity,
cannot be considered as conclusive. Furthermore, Stokin
and collaborators [72] in a recent study have conﬁrmed
that axonal defects induced by APP/PS1 mutations are not
directly caused by Aβ overproduction and amyloid accum-
ulation. These late results strengthen our observations.
While amorphous insoluble amyloid deposits do not
appear to be deleterious per se, our results support the
hypothesis of a pathogenicity of Aβ when it accumulates
intraneuronally [73, 74]. As described by others [75], young
APPxPS1micedisplayintracellularAβ accumulation,several
weeks before the occurrence of amyloid plaques. In the pre-
sent study, Aβ-positive neurons were observed, in 2-month-
old APPxPS1 mice, in speciﬁc layers of the cortex (mostly10 Journal of Aging Research
layer V). In primates, including humans, it is known that
pyramidal neurons projecting through the corpus callosum
belong to lamina III and V of the association cortex [76–78].
In mice also the origins of callosal aﬀerents have been traced
back to cell bodies in layer V [79]. By means of anterograde
tracings we conﬁrmed that the Aβ-containing neurons in the
deep layers of the cortex participate to commissural ﬁbers
passing the midline through the corpus callosum. One may
infer from these data that, early during aging, APPxPS1
mice accumulate Aβ in a subset of cortical neurons that
later become dysfunctional, develop axonal pathology (loss
of neuroﬁlament immunoreactivity and of myelin), possibly
through a dying-back mechanism [80], and eventually die
[41], leading to a deﬁnite loss of axons in brain commissures.
To summarize, we found, in APPxPS1 mutant mice
modeling AD brain amyloidosis, evidence of ﬁber tracts
atrophies. These anomalies are potentiated in aged mice
but might partly be explained by some neurodevelopmental
defect. Axonal pathology developed by APPxPS1 mice does
not appear to be caused by amorphous insoluble amyloid
deposits but intracellular Aβ that accumulates in projecting
neurons could be a causative factor. The atrophies in ﬁber
bundles we depicted in APPxPS1 mice resemble those de-
scribed in AD patients and are concomitant with a loss of
axonal neuroﬁlaments and a myelin breakdown. These re-
sults renew the importance of white matter impairments in
Alzheimer’s disease as these anomalies, with clear functional
impact, can be reproduced in mice overexpressing Aβ,a
molecular actor that is the principal target for current thera-
peutical assays in this devastating disease.
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